From a quick review, in terms of cancers being tar
Post# of 148294
(Total Views: 534)
Posted On: 01/17/2020 10:57:28 PM
Re: ClosetInvestor #15353
Quote:
From a quick review, in terms of cancers being targeted (mTNBC and Prostate, among others) and possible FDA filings, Nantkwest l (NK) has some drugs in their pipeline that are just ahead of Leronlimab and are showing similar results.
Their stock price went from $1 to $7 in the last six weeks. Could experts like ohm20 comment on this from a competitor perspective?
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼